Immobilization of proteins on liposome surface

Preparation and Catalytic Properties of Carbonic Anhydrase Conjugated to Liposomes through a Bis-Aryl Hydrazone Bond

Liposomes (lipid vesicles) with sizes of about 100-200 nm carrying surface-bound (immobilized) water-soluble enzymes are functionalized molecular compartment systems for possible applications, for example, as therapeutic materials or as catalytic reaction units for running reactions in aqueous media in vitro. One way of covalently attaching enzyme molecules under mild conditions in a controlled way to the surface of preformed liposomes is to apply the spectrophotometrically traceable bis-aryl hydrazone (BAH) bond between the liposome and the enzyme molecules of interest. Using bovine carbonic anhydrase (BCA), an aqueous dispersion of liposome-BAH-BCA - conjugates of defined composition was prepared. The liposomes used consisted of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), N-(methylpolyoxyethylene oxycarbonyl)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG), and N-(aminopropylpolyoxyethylene oxycarbonyl)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG-NH₂). The amino group of some of the DSPE-PEG-NH₂ molecules present in the liposomes were converted into an aromatic aldehyde, which (after purification) reacted with (purified) BCA molecules that had on their surface on average one acetone protected aromatic hydrazine. After purification of the liposome-BAH-BCA conjugate dispersion obtained, it was characterized in terms of (i) BCA activity, (ii) overall BCA structure, and (iii) storage stability. For an average liposome of 138 nm diameter, about 1200 BCA molecules were attached to the outer liposome surface. Liposomally bound BCA was found to exhibit (i) similar catalytic activity at 25 °C and (ii) similar storage stability when stored in a dispersed state in aqueous solution at 4 °C as free BCA. Measurements at 5 °C clearly showed that liposome-BAH-BCA is able to catalyze the hydration of carbon dioxide to hydrogen carbonate.

Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions

BACKGROUND

In this review, protein-protein interactions (PPIs) were defined, and their behaviors in normal in disease conditions are discussed. Their status at nuclear, molecular and cellular level was underscored, as for their interference in many diseases. Finally, the use of protein nanoscale structures as possible carriers for drugs targeting PPIs was highlighted.

OBJECTIVE

The objective of this review is to suggest a novel approach for targeting PPIs. By using protein nanospheres and nanocapsules, a promising field of study can be emerged.

METHODS

To solidify this argument, PPIs and their biological significance was discussed, same as their role in hormone signaling.

RESULTS

We shed the light on the drugs that targets PPI and we suggested the use of nanovectors to encapsulate these drugs to possibly achieve better results.

CONCLUSION

Protein based nanoparticles, due to their advantages, can be suitable carriers for drugs targeting PPIs. This can open a new opportunity in the emerging field of multifunctional therapeutics.

Brain delivery of proteins via their fatty acid and block copolymer modifications

It is well known that hydrophobic small molecules penetrate cell membranes better than hydrophilic molecules. Amphiphilic molecules that dissolve both in lipid and aqueous phases are best suited for membrane transport. Transport of biomacromolecules across physiological barriers, e.g. the blood-brain barrier, is greatly complicated by the unique structure and function of such barriers. Two decades ago we adopted a simple philosophy that to increase protein delivery to the brain one needs to modify this protein with hydrophobic moieties. With this general idea we began modifying proteins (antibodies, enzymes, hormones, etc.) with either hydrophobic fatty acid residues or amphiphilic block copolymer moieties, such as poy(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (pluronics or poloxamers) and more recently, poly(2-oxasolines). This simple approach has resulted in impressive successes in CNS drug delivery. We present a retrospective overview of these works initiated in the Soviet Union in 1980s, and then continued in the United States and other countries. Notably some of the early findings were later corroborated by brain pharmacokinetic data. Industrial development of several drug candidates employing these strategies has followed. Overall modification by hydrophobic fatty acids residues or amphiphilic block copolymers represents a promising and relatively safe strategy to deliver proteins to the brain.

Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions

Many proteins of interest in basic biology, translational research studies and for clinical targeting in diseases reside inside the cell and function by interacting with other macromolecules. Protein complexes control basic processes such as development and cell division but also abnormal cell growth when mutations occur such as found in cancer. Interfering with protein-protein interactions is an important aspiration in both basic and disease biology but small molecule inhibitors have been difficult and expensive to isolate. Recently, we have adapted molecular biology techniques to develop a simple set of protocols for isolation of high affinity antibody fragments (in the form of single VH domains) that function within the reducing environment of higher organism cells and can bind to their target molecules. The method called Intracellular Antibody Capture (IAC) has been used to develop inhibitory anti-RAS and anti-LMO2 single domains that have been used for target validation of these antigens in pre-clinical cancer models and illustrate the efficacy of the IAC approach to generation of drug surrogates. Future use of inhibitory VH antibody fragments as drugs in their own right (we term these macrodrugs to distinguish them from small molecule drugs) requires their delivery to target cells in vivo but they can also be templates for small molecule drug development that emulate the binding sites of the antibody fragments. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.

Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging

A new liposome-based near-infrared probe that combines both imaging and targeting abilities was developed for application in medical imaging. The near-infrared fluorescent molecule indocyanine green (ICG), and the cetuximab monoclonal antibody for epidermal growth factor receptor (EGFR) were attached to liposomes by passive adsorption. It was found that ICG molecules adsorbed to the liposomes are more fluorescent than free ICG and have a larger quantum yield. Cetuximab-adsorbed fluorescent liposomes preserved EGFR recognition, as is evident from internalization and selective binding to A431 colon carcinoma cells overexpressing EGFR. The binding of cetuximab-targeted fluorescent liposomes to A431 compared with IEC-6 cells (normal enterocytes expressing physiological EGFR levels) was greater by a factor of 3.5, ensuring imaging abilities with available fluorescent equipment. Due to relatively high quantum yield and specific tumor cell-recognizing ability, this technology deserves further in vivo evaluation for imaging and diagnostic purposes.

FROM THE CLINICAL EDITOR

A new liposome-based near-infrared probe combining both imaging and targeting abilities is reported. Due to relatively high quantum yield and EGFR-expressing tumor cell specificity, this technology deserves further in vivo evaluation for imaging and diagnostic purposes.

Liposome immunoassay (LIA) with antigen-coupled liposomes containing alkaline phosphatase

Immunoliposomes were prepared and their immunoassay applications investigated. Liposomes were prepared from cholesterol and phospholipids including maleimidobenzoylphosphatidylethanolamine (MBPE) for conjunction with thiol-containing antigens. Alkaline phosphatase (APase) was entrapped in the liposome and BSA, the antigen, was modified by reaction with 3-(2-pyridyl-dithio)propionyl N-hydroxysuccinimide ester (SPDP) to introduce thiol groups for efficient coupling. BSA-coupled liposomes (immunoliposomes) were incubated with anti-BSA serum, complement, and then with APase substrate. The amount of coupled BSA was affected by the reaction time, the composition of the liposome and the BSA concentration in the reactant. The amount of enzyme released from immunoliposomes as a final result of the immunoreaction increased with increasing concentrations of complement and antibody. The liposome immunoassay offers a relatively rapid and simple testing procedure to quantitatively or qualitatively determine the presence or absence of antibodies, or antigenic materials for diagnostic purposes.

Intrasplenic immunization with minute amounts of antigen

There are two ways to raise antibodies to minute amounts of immunogen. The first is in-vitro immunization in which the immunogen is presented to a spleen cell culture and about a week later cell fusion for hybridoma production is attempted. The second, and the subject of this review, is intrasplenic immunization, in which the immunogen is deposited into the spleen tissue and the animal itself takes care of growing the spleen cells. Both of these techniques are appropriate when only small amounts of immunogen are available. Intrasplenic immunization, however, requires less laboratory work and there is a decreased risk of contamination, often a problem with hybridoma cultures. The experience of intrasplenic immunization shows that it is the method of choice for immunization with nanogram amounts of immunogen. A successful outcome, however, requires that the immunogen is immobilized on a carrier. This review by Ove Nilsson and Anders Larsson will focus on the various types of matrix which can be used as carriers and on the procedures for transferring these carriers into the spleen tissue.

Mutual recognition between polymerized liposomes: enzyme and enzyme inhibitor system

In order to examine the usefulness of polymerized liposomes as a model for cell membranes, a mutual recognition phenomenon between different liposomes on which complementary ligands were attached was examined. We used trypsin- and soybean trypsin inhibitor (STI)-carrying polymerized liposomes to attain high sensitivities. The STI which was immobilized on the polymerized mono-dienoylphosphatidylcholine liposome showed a definite inhibitory effect on the catalytic activity of the trypsin which was immobilized on another polymerized liposome, whereas the inhibitory effect of the STI which was immobilized on the di-dienoylphosphatidylcholine liposome was much smaller than that of the mono-dienoylphosphatidylcholine system because of the larger rigity of the di-dienoylphosphatidylcholine liposome. These results suggest that the mutual recognition between complementary ligands can be realized by using polymerized liposomes with a physical stability and moderate deformability as their carriers.

Transfer of condensed viral DNA into eukaryotic cells using proteoliposomes

High-molecular-weight viral DNAs have been packed into proteoliposomes prepared by reverse-phase evaporation followed by phospholipid membrane targeting by influenza virus glycoprotein bound to hydrophobic 'anchors'. DNA has been encapsulated in the form of spermine condensates--toroidal structures sized approx. 0.1 micron, resistant to ultrasound. The efficiency of entrapping into liposomes reached 30% for condensed DNA of Mr up to 3 X 10(7). Specific infectivity of simian virus 40 DNA and simian adenovirus DNA packed into such proteoliposomes was 50- to 100-fold higher than that shown by free DNA preparations under Ca.phosphate-precipitation conditions.

A new hydrophobic anchor for the attachment of proteins to liposomal membranes

The model enzyme alpha-chymotrypsin covalently modified by a phosphatidylethanolamine derivative has been attached to liposomal membranes in high yield. A maximal protein/lipid ratio of 5.4 X 10(-3) mol enzyme/mol lipid was achieved.

Red blood cell targeting to smooth muscle cells

Monoclonal antibody discriminating between endothelial and smooth muscle cells is suggested to be used as a vector for directed transport of drugs to injured (denuded) areas of blood vessel wall. An in vitro model system was used in the studies: vascular smooth muscle or endothelial cells grown on plastic surface were treated with specific mouse monoclonal antibody recognizing an antigen localized on the surface of smooth muscle rather than endothelial cells; then erythrocytes coated with secondary (rabbit antimouse) antibodies were added. The results were analyzed spectrophotometrically or with scanning electron microscopy. Under the experimental conditions, erythrocytes, possible 'containers' for carrying the drugs, were found to bind only to smooth muscle cells. The data show that antibody provides absolute discrimination between endothelial and smooth muscle cells and, thus, may be used as a vector for drug targeting.

Targeting of enzyme immobilized on erythrocyte membrane to collagen-coated surface

It is suggested to use 'enzyme(s)-erythrocyte-antibody' complex for modulation of the microenvironment in definite compartments of blood circulation. A model system including peroxidase, human erythrocytes and anti-collagen antibodies was chosen to illustrate the principle. Peroxidase was conjugated to the erythrocyte surface via periodate-oxidized enzyme carbohydrate moiety; biotinylated antibodies were linked by avidin to the biotinylated erythrocytes. The properties of the immunocomplexes obtained have been investigated in an artificial system simulating an injured blood vessel wall. The advantages in using erythrocyte-mediated immunoenzyme complexes for enzyme (drug) targeting are discussed.

Immobilization of alpha-chymotrypsin on sucrose stearate--palmitate containing liposomes

Stable liposomes have been prepared from lipid mixture containing sucrose stearate-palmitate. 1.2 X 10(-4) mol of model enzyme alpha-chymotrypsin per mol of lipid have been coupled to prepared liposomes activated by periodate oxidation of sucrose units.

Immunoglobulins as targeting agents for liposome encapsulated drugs

Recent literature dealing with the immunoglobulin-liposome combination as a tool for drug targeting is reviewed. Mechanisms for binding of immunoglobulins to liposomes are discussed. Results obtained so far by using this concept both to induce specific liposome-cell interactions in in vitro cell cultures and to target drug containing liposomes to selected tissues in animal studies are evaluated.

Red blood cell targeting to collagen-coated surfaces

The interaction of human red blood cells carrying antihuman collagen antibody with collagen-coated surfaces was studied. Avidin was used as bifunctional crosslinking agent for the attachment of antibody to the red blood cell surface. Antibody-carrying red blood cells efficiently and specifically bound to collagen-coated surface covering a significant part of the surface. The components of normal blood had an insignificant effect on red blood cell binding. A model of drug targeting to the injured sites(s) of blood vessel wall is proposed.

Immobilization of protein molecules on liposomes. Anchorage by artificially bound unsaturated hydrocarbon tails

A method for the immobilization of trypsin, a hydrophilic nonmembrane protein, on a liposomal surface has been developed. The technique consists of covalent coupling of linoleoyl residues to the protein globules and consequent binding of linoleoyl trypsin to liposomes by a detergent dilution method. The immobilized protein preserved its biological functions: specific esterolytic catalytic activity and ability to bind to a macromolecular trypsin protein inhibitor. Liposomes carrying immobilized trypsin were able to sequester glucose with the same efficiency as liposomes without trypsin.